-
Mashup Score: 0
Background The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGFR2 inhibitor for treating advanced ovarian cancer (OC) or triple-negative breast cancer (TNBC). Methods This dose-escalation and pharmacokinetics-expansion phase 1 trial was conducted in China. We used a standard 3 + 3 dose-escalation design, with 7 dose levels tested. Patients received fuzuloparib orally twice daily, and apatinib orally once daily. The study objectives were to determine the safety profile, recommended phase 2 dose (RP2D), pharmacokinetics, preliminary efficacy, and efficacy in relation to germline BRCA mutation (gBRCAmut). Results Fifty-two pre-treated patients were enrolled (30 OC/22 TNBC). 5 (9.6%) patients had complete response, 14 (26.9%) had partial response, and 15 (28.8%) had stable disease. Objective response rate (ORR) and
Source: bmcmedicine.biomedcentral.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
Background Previous studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as a second-line therapy or beyond for treating RM-NPC patients who failed the first-line…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Promising efficacy of #apatinib plus #capecitabine in platinum-refractory #metastatic and/or #recurrent #nasopharyngeal #carcinoma in a phase II trial https://t.co/HL2wXieVJc High toxicity rate means further dose-selection investigations are required. #cancer #oncotwitter https://t.co/0sVp69dI03
-
-
Mashup Score: 7
Background Although targeted agents have been gradually applied in the treatment of HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients’ therapeutic demands are far from being met. PATHER2 was the first phase 2 trial to explore the efficacy and safety of the HER2-targeted tyrosine kinase inhibitor (TKI) pyrotinib plus the antiangiogenic agent apatinib in previously treated…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
New #clinical #cancer #research - https://t.co/pnWQz6L9Uy #Pyrotinib combined with #apatinib for targeting metastatic non-small cell #lungcancer with #HER2 alterations: a prospective, open-label, single-arm phase 2 study #PATHER2 https://t.co/Rsl8493WWO
-
-
Mashup Score: 0
ClinicalTrials.gov, NCT********.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
Necrosis in a #Biomarker-driven, Phase 2 Trial of #Adjuvant #Apatinib in Patients of #Nasopharyngeal #Carcinoma with Residual #Epstein- #Barr #Virus #DNA after #Radiotherapy https://t.co/84AiooFBft https://t.co/44LJC1tM9i
-
-
Mashup Score: 0Camrelizumab, apatinib safe, efficacious in advanced esophageal squamous cell carcinoma - 2 year(s) ago
Camrelizumab combined with apatinib may potentially be used as a second-line treatment for advanced esophageal squamous cell carcinoma, according to phase 2 results published in The Lancet Gastroenterology & Hepatology. “Second-line or later-line therapy with apatinib, a selective tyrosine kinase inhibitor of VEGF [receptor 2], showed antitumor activity in patients with advanced
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: #Camrelizumab combined with #apatinib may potentially be used as a second-line treatment for advanced esophageal squamous cell carcinoma, according to phase 2 results published in @LancetGastroHep #GITwitter https://t.co/fXtfH7Daam
-
-
Mashup Score: 2Camrelizumab, apatinib safe, efficacious in advanced esophageal squamous cell carcinoma - 2 year(s) ago
Camrelizumab combined with apatinib may potentially be used as a second-line treatment for advanced esophageal squamous cell carcinoma, according to phase 2 results published in The Lancet Gastroenterology & Hepatology. “Second-line or later-line therapy with apatinib, a selective tyrosine kinase inhibitor of VEGF [receptor 2], showed antitumor activity in patients with advanced
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Camrelizumab, #apatinib safe, efficacious in advanced esophageal squamous cell carcinoma #GITwitter @LancetGastroHep https://t.co/fXtfH7Daam
-
-
Mashup Score: 1
Camrelizumab plus apatinib showed promising antitumour activity and acceptable toxicity and could be a salvage therapy option for the treatment of high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Immune checkpoint inhibitors combined with chemotherapy for heavily-treated patients and upfront use of camrelizumab plus apatinib for patients with high-risk gestational…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in the Nov issue: #Camrelizumab plus #apatinib in patients with high-risk refractory or relapsed gestational trophoblastic neoplasia (CAP 01) https://t.co/SFCucK1PfC
-
-
Mashup Score: 1
Camrelizumab plus apatinib showed promising antitumour activity and acceptable toxicity and could be a salvage therapy option for the treatment of high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Immune checkpoint inhibitors combined with chemotherapy for heavily-treated patients and upfront use of camrelizumab plus apatinib for patients with high-risk gestational…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Camrelizumab plus #apatinib in patients with high-risk refractory or relapsed gestational trophoblastic neoplasia (CAP 01) https://t.co/SFCucK1PfC
-
-
Mashup Score: 2Apatinib, S-1 plus oxaliplatin treats locally advanced gastric cancer effectively, safely - 3 year(s) ago
In the treatment of locally advanced gastric cancer, apatinib combined with S-1 plus oxaliplatin was a safe and effective neoadjuvant treatment, according to a nonrandomized controlled study. “Neoadjuvant chemotherapy could decrease the tumor stage, increase the R0 resection rate and provide survival benefits for patients with advanced GC,” Jian-Xian Lin, MD, PhD, Fujian Medical
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: In the treatment of locally advanced #gastriccancer, #apatinib combined with S-1 plus #oxaliplatin was a safe and effective neoadjuvant treatment @JAMANetworkOpen #GITwitter #MedTwitter https://t.co/1BCpEVLKI9
-
-
Mashup Score: 4Apatinib, S-1 plus oxaliplatin treats locally advanced gastric cancer effectively, safely - 3 year(s) ago
In the treatment of locally advanced gastric cancer, apatinib combined with S-1 plus oxaliplatin was a safe and effective neoadjuvant treatment, according to a nonrandomized controlled study. “Neoadjuvant chemotherapy could decrease the tumor stage, increase the R0 resection rate and provide survival benefits for patients with advanced GC,” Jian-Xian Lin, MD, PhD, Fujian Medical
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Apatinib, S-1 plus #oxaliplatin treats locally advanced #gastriccancer effectively, safely @JAMANetworkOpen #GITwitter #MedTwitter https://t.co/1BCpEVLKI9
-
New findings from a phase 1 trial: #Fuzuloparib plus #apatinib had acceptable safety in patients with advanced #ovariancancer (OC) or triple-negative breast cancer (#TNBC): https://t.co/QI8AYj7lhR https://t.co/JIpSmZOW23